Tzvi Palash joins Protalix BioTherapeutics
Published on: 09/09/10
Protalix BioTherapeutics has appointed Tzvi Palash to the newly-created position of chief operating officer.
He will be responsible for overseeing the Israeli biotech’s manufacturing activities and implementing the expansion of its facilities.
Protalix’s chief executive Dr David Aviezer said: "Protalix is at an exciting stage in its evolution as it prepares for the anticipated launch of taliglucerase alfa for the treatment of Gaucher disease and advances its drug pipeline through clinical development.
“It is crucial that we continue to maintain the quality and supply of our product candidates as we embark on commercialisation and continue to grow. We are delighted to have Tzvi join us, given his experience in manufacturing and commercial operations.”
Tzvi has over 25 years of expertise of commercial operations in the healthcare industry and prior to joining Protalix he served as general manager at J&J subsidiary ColBar LifeScience.
Before this he was plant manager at drug manufacturing facility C.T.S., QA manager at Teva Pharmaceutical Industries and production manager at Serono’s Interpharm Laboratories subsidiary.
Mission Statement
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma jobs, pharma events, and pharma service company listings.
Site content is produced by our editorial team for InPharm.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
